Biophytis to Present Full Results of Sarconeos (BIO101) Phase 2b SARA-INT Trial in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) from September 29 to October 2, 2021



PARIS and CAMBRIDGE, Mass., Sep 29, 2021 (GLOBE NEWSWIRE) – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on developing therapies that slow down associated degenerative processes with aging and improve functional outcomes for patients with age-related diseases, including severe respiratory failure in patients with COVID-19, today announced that it will present the full results of the Sarconeos (BIO101) phase 2 SARA-INT trial in sarcopenia at the International Congress on Frailty and Sarcopenia Research (ICFSR) to be held virtually from September 29 to October 02, 2021.

The ICFSR is the key international scientific event on frailty and sarcopenia and is attended by leading researchers, physicians and Biotech / Pharma in this field.

SARA-INT results, with efficacy endpoints including a subgroup analysis and secondary endpoints, will be presented by Cendrine Tourette PhD at a dedicated seminar on Thursday, September 30 from 9:00 a.m. to 9:30 a.m. EDT. The seminar will be followed by a question and answer session with representatives of Biophytis: Cendrine Tourette, PhD (SARA project manager), Jean Mariani, MD, PhD (director of the board of directors) and Waly Dioh, PhD (chief operations). The question-and-answer session will be moderated by Roger A. Fielding, PhD, principal investigator of the SARA-INT trial and who leads the Nutrition, Exercise Physiology and Sarcopenia team at Tufts University in Boston.

Biophytis previously announced the first results of the SARA-INT study. The data showed that Sarconeos (BIO101) at the highest dose (350 mg bid) demonstrated clinically significant improvement in the 400 meter walk test (400MWT), the primary endpoint of the study. Sarconeos (BIO101) showed a very good tolerance profile at doses of 175 mg bid and 350 mg bid. Based on the results of SARA-INT, Biophytis is currently preparing the phase 3 program and the interactions of associated regulatory agencies.

Biophytis SA is a clinical-stage biotechnology company specializing in the development of therapies aimed at slowing the degenerative processes associated with aging and improving the functional outcomes of patients with age-related diseases, including severe respiratory failure in patients with COVID-19. . Sarconeos (BIO101), our lead drug candidate, is an orally administered small molecule under development as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA -INT). It is also being investigated in a two-part Phase 2-3 (COVA) clinical study for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America and the United States. A pediatric formulation of Sarconeos (BIO101) is under development for the treatment of Duchenne muscular dystrophy (DMD). The Company is based in Paris, France, and Cambridge, Massachusetts.

The Company’s ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADS (American Depositary Shares) are listed on Nasdaq Capital Market (ticker BPTS –ISIN: US09076G1040). For more information, visit

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify such forward-looking statements by using words such as “prospect”, “believes”, “expects”, “,”, “” might “,” seeks “,” predicts “,” a intention “,” trends “,” plans “,” estimates “,” forecasts “or the negative version of these or other comparable words. These forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in these forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or currently considered. as insignificant by Biophytis. or there are material factors that could cause actual results to differ materially from those shown in such statements. Please also refer to the section “Risks and uncertainties facing the Company” of the Company’s 2020 annual report available on the BIOPHYTIS website ( and as set out in the section “Factors of risk ”of Form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We assume no obligation to update or publicly review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Biophytis Contact for Investor Relations
Evelyne Nguyen, Chief Financial Officer

Media contact
Life science advisors
Sophie Baumont
T: +33 6 27 74 74 49

Investor Relations
LifeSci Advisors, LLC
Ligia Vela-Reid



Leave A Reply